

Bergen Municipal Employee Benefits Fund

Q1 2023

Top Line Performance Metrics

BERGEN MUNICIPAL EMP			
Description	Q1 2023	Q1 2022	Change
Avg Subscribers per Month	1,273	1,100	15.7%
Avg Members per Month	2,963	2,516	17.8%
Number of Unique Patients	1,877	1,450	29.4%
Pct Members Utilizing Benefit	63.3%	57.6%	5.7
Plan Cost Net	\$1,098,248	\$739,904	48.4%
Total Days	367,096	304,023	20.7%
Total Adjusted Rxs	13,916	11,377	22.3%
Average Member Age	37.9	38.4	-1.2%
Plan Cost Net PMPM	\$123.55	\$98.03	26.0%
Plan Cost Net/Day	\$2.99	\$2.43	22.9%
Plan Cost Net per Adjusted Rx	\$78.92	\$65.04	21.3%
Nbr Adjusted Rxs PMPM	1.57	1.51	3.9%
Generic Fill Rate	85.6%	86.4%	-0.9
90 Day Utilization	67.0%	65.2%	1.7
Retail - Maintenance 90 Utilization	41.1%	43.5%	-2.4
Home Delivery Utilization	25.9%	21.7%	4.1
Member Cost Net %	18.4%	21.5%	-3.1
Specialty Percent of Plan Cost Net	43.7%	39.5%	4.2
Specialty Plan Cost Net PMPM	\$54.01	\$38.76	39.3%
Formulary Compliance Rate	97.4%	97.4%	0.1

Government - Northeast Region	
Q1 2023	Change
41.8	-0.2%
\$153.32	6.2%
\$2.98	3.5%
\$80.26	3.2%
1.91	3.0%
86.1%	-0.1
71.2%	0.2
26.5%	1.9
44.7%	-1.7
13.3%	1.2
48.5%	-1.3
\$74.39	3.4%
98.1%	0.4



Key Statistics: Specialty Detailed

Description	BERGEN MUNICIPAL EMP					
	Non-Specialty			Specialty		
	Q1 2023	Q1 2022	Change	Q1 2023	Q1 2022	Change
Avg Subscribers per Month	1,273	1,100	15.7%	1,273	1,100	15.7%
Avg Members per Month	2,963	2,516	17.8%	2,963	2,516	17.8%
Number of Unique Patients	1,871	1,444	29.6%	57	45	26.7%
Pct Members Utilizing Benefit	63.1%	57.4%	5.8	1.9%	1.8%	0.1
Total Plan Cost Net	\$618,161	\$447,320	38.2%	\$480,087	\$292,584	64.1%
Percent of Total Plan Cost Net	56.3%	60.5%	-4.2	43.7%	39.5%	4.2
Total Days	361,661	299,760	20.7%	5,435	4,263	27.5%
Total Adjusted Rxs	13,722	11,217	22.3%	194	160	21.3%
Percent of Total Adjusted Rxs	98.61%	98.59%	0.0	1.39%	1.41%	0.0
Plan Cost Net PMPM	\$69.54	\$59.26	17.3%	\$54.01	\$38.76	39.3%
Plan Cost Net/Day	\$1.71	\$1.49	14.5%	\$88.33	\$68.63	28.7%
Plan Cost Net per Adjusted Rx	\$45.05	\$39.88	13.0%	\$2,474.67	\$1,828.65	35.3%
Nbr Adjusted Rxs PMPM	1.54	1.49	3.9%	0.02	0.02	3.0%
Generic Fill Rate	86.5%	87.4%	-1.0	22.2%	16.9%	5.3
Member Cost Net %	13.6%	16.7%	-3.1	23.8%	27.8%	-4.0

Specialty Government - Northeast Region	
Q1 2023	Change
\$74.39	3.4%
\$118.62	-4.2%
\$3,310.58	-4.4%
0.02	8.2%
22.8%	0.2
14.9%	2.8



Top 10 Indications

Top Indications by Plan Cost Net																
Q1 2023										Q1 2022					% Change	
Rank	Peer Rank	Indication	Adjusted		Plan Cost Net	Generic Fill Rate	Peer Generic Fill Rate	Plan Cost Net PMPM	Rank	Adjusted		Plan Cost Net	Generic Fill Rate	Plan Cost Net PMPM	Plan Cost Net PMPM	Plan Cost Net PMPM
			Rxs	Patients						Rxs	Patients					
1	3	DIABETES	954	173	\$125,379	32.9%	36.0%	\$14.10	2	841	139	\$88,010	37.5%	\$11.66	\$11.66	21.0%
2	1	INFLAMMATORY CONDITIONS	94	32	\$112,081	59.6%	49.7%	\$12.61	1	78	22	\$98,740	60.3%	\$13.08	\$13.08	-3.6%
3	2	CANCER	64	24	\$110,595	82.8%	84.1%	\$12.44	8	55	20	\$29,219	94.5%	\$3.87	\$3.87	221.4%
4	54	MUSCULAR DYSTROPHIES	5	1	\$85,088	0.0%	0.0%	\$9.57	3	6	1	\$70,820	0.0%	\$9.38	\$9.38	2.0%
5	8	ASTHMA	527	215	\$54,873	75.1%	71.3%	\$6.17	4	385	158	\$42,064	69.9%	\$5.57	\$5.57	10.8%
6	5	ANTICOAGULANT	160	51	\$46,347	15.0%	20.4%	\$5.21	5	140	41	\$36,118	17.1%	\$4.79	\$4.79	9.0%
7	7	WEIGHT LOSS	66	30	\$42,489	12.1%	11.5%	\$4.78	9	54	26	\$27,648	29.6%	\$3.66	\$3.66	30.5%
8	43	TARDIVE DYSKINESIA	6	1	\$33,404	0.0%	4.2%	\$3.76								
9	6	SKIN CONDITIONS	158	115	\$32,528	83.5%	87.3%	\$3.66	7	140	96	\$35,068	80.7%	\$4.65	\$4.65	-21.2%
10	33	GROWTH DEFICIENCY	23	7	\$30,522	0.0%	0.0%	\$3.43	6	18	7	\$35,544	0.0%	\$4.71	\$4.71	-27.1%
Total Top 10:			2,057		\$673,307	47.8%		\$75.75		1,717		\$463,231	48.7%	\$61.37		23.4%
Differences Between Periods:			340		\$210,076	-0.9%		\$14.37								

The largest financially impactful change was in Cancer, driving \$81.4K in increased net cost for a 221.4% increase in Net PMPM

Cancer trend increased 221.4%, contributing an additional \$8.57 to Net PMPM

Represent 61.3% of your total Plan Cost Net

Peer = Express Scripts Peer 'Government - Northeast Region' market segment

Top 25 Drugs

Top Drugs by Plan Cost Net																	
Q1 2023											Q1 2022						
Peer Rank	Rank	Brand Name	Indication	Adj. Rxs	Pts.	Plan Cost Net	Plan Cost Net	Peer Plan Cost Net	Rank	Adj. Rxs	Pts.	Plan Cost Net	Plan Cost Net	Peer Plan Cost Net	% Change		
							PMPM	PMPM				PMPM	PMPM	PMPM			
1	181	EMFLAZA*	MUSCULAR DYSTROPHIES	5	1	\$85,088	\$9.57	\$0.18	1	6	1	\$70,820	\$9.38		2.0%	0.7%	
2	29	POMALYST*	CANCER	2	1	\$41,156	\$4.63	\$0.94								16.1%	
3	2	OZEMPIC	DIABETES	80	30	\$39,114	\$4.40	\$4.90	6	49	14	\$20,807	\$2.76		59.6%	88.5%	
4	109	INGREZZA*	TARDIVE DYSKINESIA	6	1	\$33,404	\$3.76	\$0.31								95.7%	
5	5	WEGOVY	WEIGHT LOSS	43	17	\$32,589	\$3.67	\$3.55	4	31	13	\$23,299	\$3.09		18.8%	178.5%	
6	357	MEKINIST*	CANCER	3	1	\$29,985	\$3.37	\$0.08								12.2%	
7	379	TAFINLAR*	CANCER	3	1	\$27,617	\$3.11	\$0.07								315.5%	
8	376	COSENTYX (2 SYRINGES)*	INFLAMMATORY CONDITIONS	2	1	\$23,920	\$2.69	\$0.07								5.6%	
9	4	ELIQUIS	ANTICOAGULANT	69	23	\$23,373	\$2.63	\$4.20	8	53	17	\$17,287	\$2.29		14.8%	10.3%	
10	64	NUCALA*	ASTHMA	6	2	\$22,739	\$2.56	\$0.53	5	4	1	\$23,059	\$3.05		-16.3%	37.7%	
11	3	STELARA*	INFLAMMATORY CONDITIONS	4	1	\$22,024	\$2.48	\$4.70	2	7	2	\$37,385	\$4.95		-50.0%	3.8%	
12	16	XARELTO	ANTICOAGULANT	67	21	\$21,647	\$2.44	\$1.38	7	63	19	\$18,784	\$2.49		-2.1%	-2.2%	
13	58	NORDITROPIN FLEXPRO*	GROWTH DEFICIENCY	9	3	\$19,838	\$2.23	\$0.59	3	15	6	\$34,574	\$4.58		-51.3%	-3.7%	
14	6	TRULICITY	DIABETES	39	14	\$19,269	\$2.17	\$2.46	10	35	11	\$13,888	\$1.84		17.8%	-6.7%	
15	1	HUMIRA(CF) PEN*	INFLAMMATORY CONDITIONS	5	2	\$17,380	\$1.96	\$6.98	15	5	2	\$11,725	\$1.55		25.9%	12.5%	
16	10	FLOWFLEX COVID-19 AG HOME TEST	DIAGNOSTIC AIDS	175	140	\$15,645	\$1.76	\$1.65	137	18	17	\$956	\$0.13		1290.2%	466.1%	
17	15	VYVANSE	ATTENTION DISORDERS	56	26	\$15,195	\$1.71	\$1.44	28	31	13	\$6,958	\$0.92		85.5%	27.9%	
18	561	DEFERASIROX*	IRON TOXICITY	6	1	\$12,901	\$1.45	\$0.04								-49.0%	
19	165	XIAFLEX*	MISC CONDITIONS	1	1	\$12,238	\$1.38	\$0.20								18.6%	
20	217	PIRFENIDONE*	IDIOPATHIC PULMONARY FIBROSIS	4	1	\$11,899	\$1.34	\$0.14									
21	8	DUPIXENT PEN*	SKIN CONDITIONS	6	2	\$11,040	\$1.24	\$2.09	9	9	2	\$17,147	\$2.27		-45.3%	52.6%	
22	56	REXULTI	MENTAL/NEURO DISORDERS	9	2	\$10,964	\$1.23	\$0.60	49	3	1	\$3,331	\$0.44		179.5%	2.8%	
23	199	ENTYVIO*	INFLAMMATORY CONDITIONS	2	1	\$10,296	\$1.16	\$0.16	18	2	1	\$9,412	\$1.25		-7.1%	-12.8%	
24	7	ENBREL SURECLICK*	INFLAMMATORY CONDITIONS	6	2	\$10,206	\$1.15	\$2.23	34	3	1	\$5,535	\$0.73		56.6%	19.8%	
25	118	ZEPOSIA*	MULTIPLE SCLEROSIS	2	1	\$9,825	\$1.11	\$0.28								162.0%	
Total Top 25:				610		\$579,351	\$65.18	\$39.77		334		\$314,966	\$41.73		56.2%	30.3%	
Differences Between Periods:				276		\$264,385	\$23.45	\$9.25									

*Specialty Drugs

Represent 50.7% of your total Plan Cost Net and comprise 17 indications

17 of your top 25 are specialty drugs, making up 69.3% of your Top 25 spend

Peer = Express Scripts Peer 'Government - Northeast Region' market segment